secwatch.observer — SEC 8-K summary
======================================

Issuer:     X4 Pharmaceuticals, Inc (XFOR)
CIK:        0001501697
Form:       8-K
Filed at:   2021-10-19T23:59:59+00:00
Accession:  0001628280-21-020237
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

X4 Pharmaceuticals appoints Francoise de Craecker to Board and Compensation Committee
--------------------------------------------------------------------------------

- Francoise de Craecker appointed as Class III director effective Oct 14, 2021, term through 2023 annual meeting.
- She replaces Alison Lawton on the Compensation Committee; Lawton remains on the Board.
- Received initial option to purchase 12,250 shares vesting over three years, with full acceleration on change of control.
- Compensation follows standard non-employee director policy as described in the 2021 proxy statement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501697/000162828021020237/0001628280-21-020237-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501697/000162828021020237/xfor-20211014.htm
  HTML page:      https://secwatch.observer/filing/0001628280-21-020237

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer